Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty

This is a prospective randomized double blind trial of patients undergoing selective laser
trabeculoplasty for primary open angle glaucoma and ocular hypertension. Enrolled patients
are randomized to receive one drop of brimonidine 0.1% in one eye and one drop of
apraclonidine 0.5% in the fellow eye. The trabecular meshwork in both eyes of each enrolled
patient is treated 360 degrees at the same sitting. Intraocular pressure is measured in each
eye one hour before applying the study medications and at one hour and one week after laser
surgery.

Inclusion Criteria:

- male or female, at least 18 years of age

- Open Angle Glaucoma with inadequate intraocular pressure (IOP) control or evidence of
progression (based on optic nerve head appearance and/or visual field changes)
despite current medical therapy

- Ocular Hypertension requiring lowering of IOP

- ability to understand and provide informed consent to participate in this study and
willingness to follow study instructions and likely to complete all required visits

Exclusion Criteria:

- inability to understand and provide informed consent to participate in this study

- inability/unwillingness to follow study instructions and complete all required visits

- Documented allergy to either brimonidine or iopidine

- Angle Closure Glaucoma

- Congenital/Juvenile Glaucoma

- Neovascular Glaucoma

- Active uveitis